Literature DB >> 10214784

Nasal nitric oxide does not control basal nasal patency or acute congestion following allergen challenge in allergic rhinitis.

P E Silkoff1, Y Roth, P McClean, P Cole, J Chapnik, N Zamel.   

Abstract

Nasal nitric oxide (NO), a powerful vasodilator, could control the filling of nasal capacitance vessels, thus determining nasal patency and mediating the acute congestion accompanying allergen challenge. We examined the effect of topical N-nitro-L-arginine-methyl-ester (L-NAME; 100 to 200 mg), an NO synthase inhibitor, on nasal NO and on nasal patency assessed by acoustic rhinometry in 7 subjects with nasal allergy, and in 4 subjects we examined the effects of nasal allergen challenge on nasal NO before and after a short course of nasal steroid. After L-NAME, nasal NO fell to 42.1%+/-15.7% of baseline (p < .0001) with no significant change in minimal cross-sectional area. After allergen challenge, acute congestion was associated with a significant fall in nasal NO, which returned to baseline by 4 hours, when the congestion resolved. Repeat challenge after 2 weeks of nasal corticosteroid yielded similar findings. A role for NO in modulating vascular tone was not supported by the present study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10214784     DOI: 10.1177/000348949910800409

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  3 in total

1.  [Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis].

Authors:  L Klimek; P Högger; O Pfaar
Journal:  HNO       Date:  2012-07       Impact factor: 1.284

Review 2.  Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis.

Authors:  M Okano
Journal:  Clin Exp Immunol       Date:  2009-08-06       Impact factor: 4.330

Review 3.  Objective monitoring of nasal patency and nasal physiology in rhinitis.

Authors:  Robert A Nathan; Ron Eccles; Peter H Howarth; Sverre K Steinsvåg; Alkis Togias
Journal:  J Allergy Clin Immunol       Date:  2005-03       Impact factor: 10.793

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.